1. Cyhoeddwyd

   Adverse drug reactions in economic evaluations

   Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

2. Cyhoeddwyd

   Adverse drug reactions in economic evaluations

   Hughes, D. & Hughes, D. A., 1 Maw 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

3. Cyhoeddwyd

   Adverse drug reactions in economic evaluations

   Hughes, D. & Hughes, D. A., 1 Gorff 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   Adverse drug reactions, multimorbidity and polypharmacy: A prospective analysis of one month of medical admissions

   Osanlou, R., Walker, L., Hughes, D., Burnside, G. & Pirmohamed, M., 4 Gorff 2022, Yn: BMJ Open. 12, 7, e055551.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   Adverse drug reactions: analysis by regulatory authorities and by economists

   Hughes, D. & Hughes, D. A., 1 Ebr 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

6. Cyhoeddwyd

   Affordable orphan drugs: A role for not-for-profit organisations

   Davies, E. H., Fulton, E., Brook, D. & Hughes, D., Gorff 2017, Yn: British Journal of Clinical Pharmacology. 83, 7, t. 1595-1601

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

8. Cyhoeddwyd

   All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

9. Cyhoeddwyd

   All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

10. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn